Lataa...
Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs Approved Between 2011 and 2017
This review of novel oncology drugs approved by the US Food and Drug Administration examines the use of surrogate end points for overall survival, evaluates the use of patient-reported outcomes in trials supporting approvals, and seeks to determine whether drugs initially approved without evidence o...
Tallennettuna:
| Julkaisussa: | JAMA Oncol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Medical Association
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6613294/ https://ncbi.nlm.nih.gov/pubmed/31268471 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1760 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|